FDA Rejects Titan’s Probuphine Despite Positive Panel Vote
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s “complete response” letter for abuse-resistant buprenorphine for opioid dependence follows an advisory committee that aired concerns about efficacy and adequate dosing, as well as questioning the proposed Risk Evaluation and Mitigation Strategy.